Newsfiscal.ai
Wedbush Adjusts Avalo Therapeutics Price Target to $22
· Published
Article summary
Wedbush Securities has adjusted its price target for Avalo Therapeutics, Inc. to $22 from $34 while maintaining an Outperform rating.
An excerpt from the original article.Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…